Overview

Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure

Status:
Active, not recruiting
Trial end date:
2023-07-31
Target enrollment:
Participant gender:
Summary
Effective diuresis is the primary goal of most acute decompensated heart failure hospitalizations, but diuretic resistance is common and our ability to detect it is limited. Further, there are therapeutically distinct groups of diuretic-resistant patients. These are not easily distinguished using currently available methods, leading to trial-and-error based treatment that promotes lengthy hospitalizations. The aims of this study are: 1. To develop inexpensive and efficient tools to predict diuretic response 2. To understand the prevalence of therapeutically targetable mechanisms of diuretic resistance using endogenous lithium clearance 3. To develop methodology to differentiate diuretic resistance mechanisms using common/inexpensive laboratory tests 4. To provide proof of concept that mechanistically tailored diuretic therapy can improve natriuresis
Phase:
Phase 1
Details
Lead Sponsor:
Yale University
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Bumetanide
Chlorothiazide
Diuretics
Furosemide
Sodium Potassium Chloride Symporter Inhibitors